I happened accross this board by accident, and was surprised to see so few contributors given that 45% of shares are now held in the US (figure correct at 3/98).
I'm in the UK, and wondered if you had seen a news item reported here in a May edition of the Daily Mail newspaper. According to this, Galantamine (Reminyl) has been on sale in Austria since 1996 following a small (N = 200) but promising clinical trial. It has already taken 50% of the market, and has knocked the previous leader, Pfizer's Aricept, down to 40%. Worldwide, Aricept had sales of around �50m ($80m) in the last quarter, so if the Austrian situation were replicated world-wide this would have an enormous effect on SHPGY's turnover and profitability.
I own the stock but have never seen such a statistic. Where did you see this or can you provide a link. SHPGY is developing an interesting list of large institutional holders who will create a substantial base from which the stock can run. Given some good news on the clinical front and/or continued remarkable Adderall strength, the upside is significant.
I read the story in a UK newspaper called the Daily Mail. I know that it was in the week 18th - 22nd May, because I made dated notes immediately before and after. As far as I know there is no online version of the Daily Mail, but if you doubt the veracity of the story, you could always email Shire and ask for the press cutting - most companies keep them.